Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%

Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India, says GlobalData

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke

Bayer’s Vividion emerging as significant player in San Diego Biotech hub

Bayer now present in four of the largest biotechnology hubs in the United States

Bayer posts higher sales, profit in first quarter

Company's net income rose by 57.5 percent to 3.291 billion euros in Q1

Bayer to invest €1.3 billion for driving innovations in life sciences, agriculture segment

Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024

Bayer to set up 27 telemedicine centres across eight states

Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya

Bayer highlights pharma business plans on Media Day

Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)